Disala Fernando

Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects

Navin Goyal, Peter J. Skrdla, Rosemary Schroyer et al. · American Journal of Cardiovascular Drugs · 2019 · 147 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

A Randomised Trial Evaluating the Effects of the TRPV1 Antagonist SB705498 on Pruritus Induced by Histamine, and Cowhage Challenge in Healthy Volunteers

Rachel A. Gibson, Jon Robertson, Harshna Mistry et al. · PLoS ONE · 2014 · 78 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6⁺ cells in an experimental suction blister

Gerben Bouma, Stefano Zamuner, Kirsty Hicks et al. · British Journal of Clinical Pharmacology · 2017 · 47 citations · Full text

Medicine, Immunology, Pharmacology +17

<i>In vivo</i> affinity and target engagement in skin and blood in a first‐time‐in‐human study of an anti‐oncostatin M monoclonal antibody

Juliet Reid, Stefano Zamuner, Ken Edwards et al. · British Journal of Clinical Pharmacology · 2018 · 47 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study

Inge Sutanto, Amin Soebandrio, Lenny L. Ekawati et al. · The Lancet Infectious Diseases · 2023 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16